SSC
BIO icon

Syverson Strege & Co’s Bio-Rad Laboratories Class A BIO Stock Holding History

Syverson Strege & Co’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-5
Closed -$2.4K – 126
2023
Q1 		$2.4K Buy
+5
New +$2.34K ﹤0.01% 456
2021
Q4 		– Sell
-3
Closed -$2K – 323
2021
Q3 		$2K Buy
+3
New +$2.25K ﹤0.01% 389

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Syverson Strege & Co's BIO Position: Q2 2023 in Review

Syverson Strege & Co sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2023, closing a stake of 5 shares — an estimated $2.4K sold.

Syverson Strege & Co first reported a position in BIO in Q3 2021 and held it in 2 quarters. The position peaked at $2.4K in Q1 2023. 468 funds tracked by Wall St. Rank hold BIO as of Q2 2023.

  • Syverson Strege & Co reported no remaining Bio-Rad Laboratories Class A position as of Q2 2023 after selling out during the quarter.
  • Syverson Strege & Co sold 5 Bio-Rad Laboratories Class A shares in Q2 2023, an estimated $2.4K.
  • Syverson Strege & Co first reported a position in Bio-Rad Laboratories Class A in Q3 2021 and held it in 2 quarters.
  • Syverson Strege & Co's Bio-Rad Laboratories Class A position peaked at $2.4K in Q1 2023.
  • 468 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2023.

Based on Syverson Strege & Co's 13F filing for Q2 2023, filed 4 Aug 2023.